In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
News|Podcasts|January 19, 2026
ACT Brief: Closing Gender Gaps in Parkinson’s Research, Startup Communication Breakdowns, and a New White House Healthcare Plan
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we look at efforts to address sex-based evidence gaps in Parkinson’s disease research, why communication failures continue to delay study startup, and how a new White House healthcare plan aims to reduce drug and insurance costs.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- A new Applied Clinical Trials contributed article
examines how women remain underrepresented in Parkinson’s disease research despite accounting for a large share of patients worldwide. Persistent gaps in sex-stratified data continue to limit precision medicine approaches. Programs such as the Critical Path Institute’s GEM-PD initiative are working to improve inclusion through digital health tools and real-world data. - In an Applied Clinical Trials video
interview , Brian Mallon of ICON says communication breakdowns between sponsors, CROs, and sites remain a major driver of delayed study startup. He notes that communication is often one-directional and fails to adequately support site needs. Improving collaboration, he says, is key to reducing activation timelines. - On January 15, President Trump
announced the Great Healthcare Plan, which proposes lowering healthcare costs through drug price reforms and greater pricing transparency. The plan includes most-favored-nation drug pricing and new disclosure requirements for insurers and providers. The White House says the proposal is designed to deliver direct cost savings to patients.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.
Trending on Applied Clinical Trials Online
1
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
2
Mixed Outsourcing Models Are Spreading. Is Sponsor Oversight Keeping Up?
3
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
4
Hierarchical Endpoints in Cardiology: How Much Treatment Benefit, and From Where
5